No services found
No Products found
100µg
Homo sapiens (Human)
AntibodySystem
AntibodySystem, Recombinant Proteins
Escherichia coli (E. coli)
Procaryotic expression
Recombinant human PPBP/CXCL7/NAP-2, N-His is a protein that plays a crucial role in inflammatory responses and has been identified as a potential drug target for various inflammatory diseases. In this article, we will discuss the structure, activity, and potential applications of this protein.
Recombinant human PPBP/CXCL7/NAP-2, N-His is a chemokine protein that belongs to the CXC subfamily of chemokines. It is a small protein of 70 amino acids with a molecular weight of approximately 8 kDa. The protein contains a conserved N-terminal region and a C-terminal region that is highly variable. Recombinant human PPBP/CXCL7/NAP-2, N-His is produced through recombinant DNA technology, which allows for the production of large quantities of the protein in a controlled environment.
Recombinant human PPBP/CXCL7/NAP-2, N-His is a potent chemoattractant for neutrophils, monocytes, and T cells. It is also involved in the regulation of leukocyte adhesion and migration, as well as angiogenesis. The protein binds to the CXCR1 and CXCR2 receptors, which are expressed on the surface of various immune cells. Upon binding, it initiates a signaling cascade that leads to the recruitment and activation of immune cells to the site of inflammation.
Recombinant human PPBP/CXCL7/NAP-2, N-His has been identified as a potential drug target for various inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In these diseases, there is an abnormal increase in the production of the protein, leading to chronic inflammation. By targeting this protein, it is possible to reduce the recruitment and activation of immune cells, thereby reducing inflammation and its associated symptoms.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints. The overproduction of pro-inflammatory cytokines, including PPBP/CXCL7/NAP-2, has been implicated in the pathogenesis of RA. Recombinant human PPBP/CXCL7/NAP-2, N-His can be used as a potential therapeutic agent to inhibit the recruitment and activation of immune cells, thereby reducing inflammation and joint damage in RA patients.
Psoriasis is a chronic inflammatory skin disorder characterized by red, scaly patches on the skin. The increased expression of PPBP/CXCL7/NAP-2 has been observed in psoriatic lesions. By targeting this protein, it is possible to reduce the infiltration of immune cells into the skin, thereby reducing inflammation and improving the symptoms of psoriasis.
Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder of the gastrointestinal tract. PPBP/CXCL7/NAP-2 has been found to be overexpressed in the inflamed intestinal tissue of IBD patients. By targeting this protein, it is possible to reduce the recruitment of immune cells to the gut, thereby reducing inflammation and improving the symptoms of IBD.
Recombinant human PPBP/CXCL7/NAP-2, N-His is a small chemokine protein that plays a critical role in inflammatory responses.
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
First name
Last name
Email address
Lab / Company
Phone number
Message
send
Your cart is currently empty.